Search

Author/Creator Bongardt, S.

1. FRI0002 Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Cynomolgus Monkeys and in Patients with Systemic Lupus Erythematosus. (9th June 2015)

Authors:
Shock, A.; Kilgallen, B.; Koetse, W.; Stach, C.; Bongardt, S.; Galateanu, C.; Brackenbury, L.; Williams, N.; Wolfreys, A.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 74(2015)Supplement 2
Page Start:
420
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study. Issue 4 (24th March 2016)

Authors:
Wallace, D. J.; Hobbs, K.; Clowse, M. E. B.; Petri, M.; Strand, V.; Pike, M.; Merrill, J. T.; Leszczyński, P.; Neuwelt, C. M.; Jeka, S.; Houssiau, F.; Keiserman, M.; Ordi‐Ros, J.; Bongardt, S.; Kilgallen, B.; Galateanu, C.; Kalunian, K.; Furie, R.; Gordon, C.
Journal:
Arthritis care & research
Issue:
Volume 68:Issue 4(2016:Apr.)
Page Start:
534
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus. (10th June 2014)

Authors:
Furie, R.A.; Petri, M.; Gordon, C.; Strand, V.; Galateanu, C.; Bongardt, S.; Koetse, W.; Wallace, D.J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 73:Supplement 2(2014)
Page Start:
184
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. THU0272 Epratuzumab Maintains Improvements in Disease Activity for Over 2 Years in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008). (23rd January 2014)

Authors:
Gordon, C.; Clowse, M.; Houssiau, F.; Petri, M.; Kilgallen, B.; Kalunian, K.; Strand, V.; Bongardt, S.; Wallace, D. J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 72:Supplement 3(2013)
Page Start:
A257
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. THU0277 Epratuzumab: Sustained Safety Profile and Effect on Corticosteroid Use on Long-Term Treatment in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008). (23rd January 2014)

Authors:
Wallace, D. J.; Ordi-Ros, J.; Neuwelt, M.; Kalunian, K.; Kilgallen, B.; Bongardt, S.; Petri, M.; Pike, M.; Jeka, S.; Gordon, C.; Strand, V.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 72:Supplement 3(2013)
Page Start:
A259
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. THU0286 Immunologic Response to Long-Term Epratuzumab Treatment in Sl0008, An Open-Label Long-Term Extension Study in Patients with Moderate-to-Severe Systemic Lupus Erythematosus. (23rd January 2014)

Authors:
Strand, V.; Leszczyński, P.; Keiserman, M.; Kilgallen, B.; Bongardt, S.; Wallace, D. J.; Gordon, C.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 72:Supplement 3(2013)
Page Start:
A262
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗